AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 131 min read$ZVRA

McFarlane Neil F. sold $225K of ZVRA

McFarlane Neil F. (President and CEO) sold 20,000 shares of ZEVRA THERAPEUTICS, INC. (ZVRA) at $11.25 ($0.22M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · McFarlane Neil F.
Published Oct 13, 2026, 8:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ZVRA
Bearish
medium confidence
Mentioned
$ZVRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZVRABearishLow
01

Why it matters

The modest size of the sale suggests limited immediate price impact, but it may influence short‑term sentiment among retail and institutional holders.

02

Market read

A primary‑source insider sale that could cause slight downward pressure on ZVRA, but the effect is likely limited given the modest transaction size.

03

What to watch

Potential upcoming clinical data releases or partnership news could offset the sell‑off pressure.

Relevance 3/10Novelty 3/10Timing: post‑market filing

Background

Form 4 disclosures provide transparent insight into insider transactions. This filing shows the CEO executed a pre‑arranged sale, a common practice for liquidity or tax planning.

Company-level read

Ticker impact

$ZVRABearishMedium confidence
Context

CEO Neil F. McFarlane sold 20,000 shares for $224,948 via a 10b5‑1 plan, reducing his stake to 417,225 shares.

Expected impact

likely slight pressure as investors digest the insider sell

Evidence & confidence

Form 4 filings are primary source disclosures; a $225 K sale by the CEO is material enough to affect sentiment but the amount is modest for a mid‑cap biotech.

Market effects

Sector

Minor impact on the biotech sector; similar insider sales often prompt short‑term caution.

Regional

U.S. market only; no broader regional effect.

Global

Limited to investors tracking ZVRA.

Counterpoint

What could challenge this read

The sale could be routine under a 10b5‑1 plan and not indicative of negative fundamentals.

Key entities

  • person
    Neil F. McFarlane

    President and CEO of ZEVRA Therapeutics, Inc.

  • company
    ZEVRA Therapeutics, Inc.

    Biotech firm focused on rare disease therapies, ticker ZVRA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ZVRA insider trading history →

Related articles

AUG 7
$ZVRAMed

Zevra Therapeutics Q2 Earnings Call Highlights

Zevra Therapeutics (NASDAQ:ZVRA) reported Q2 updates on MIPLYFFA, including high refill, compliance and persistence, and payer coverage of 69% of covered lives. Net reimbursements were $9 million. In the EU, Zevra will re-examine arimoclomol after a CHMP negative opinion, with an expected Q4 decision. Cash was $260.2 million.

yahoo.com4 min
AUG 5
$ZVRAMed

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

ZEVRA THERAPEUTICS, INC. (ZVRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zevra Reports Second Quarter 2026 Financial Results and Corporate Update $39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position of $260.2

SEC EDGAR 8-K6 min
JUL 24
$ZVRAMedAI 8/10

Zevra Slips on Revealing Opinion on Treatment

Zevra Therapeutics (NASDAQ: ZVRA) fell after the EMA CHMP issued a negative opinion on its marketing authorization application for arimoclomol to treat Niemann-Pick disease type C. Zevra said it will request a re-examination and provide supporting explanations, and it continues expanded access to support eligible patients and gather real-world evidence.

baystreet.ca2 min